Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

NCT02417142 · Completed

Last updated 2026-05-28

This clinical trial is testing whether weekly injections of exenatide, added to usual treatments, can help reduce negative symptoms in adults with schizophrenia or schizoaffective disorder.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 70 people

Who can join Ages 18–65 · all sexes

Timeline Started 2014-09 · est. completion 2020-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02417142 ↗

Description as written by the study sponsor.

This is a 24-week, randomized, double-blind, placebo-controlled trial of exenatide weekly injection (2mg per dose) as an adjunctive therapy in 70 schizophrenia subjects to examine exenatide's effects on negative symptoms and cognition.

Treatments tested

Exenatide also known as Bydureon Drug

Exenatide SQ 2mg/week for 24 weeks.
Placebo also known as Control Drug

Placebo SQ 1x/week for 24 weeks.

Main thing measured	Negative Symptoms as Measured by the Scale for the Assessment of Negative Symptoms (SANS) Total Score
Sponsor	University of Massachusetts, Worcester
Conditions studied	Schizophrenia, Schizoaffective Disorder
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02417142 ↗